Bruton's tyrosine kinase as anti-cancer drug target
Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.
1. A method of treating cancer, comprising:
a) providing:
i) subject with breast cancer,
ii) a chemotherapeutic agent, and
iii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase, wherein said inhibitor comprises an interfering double stranded RNA selected from the group consisting of: sense strand having the nucleotide sequence of SEQ ID NO: 66, an antisense strand having the nucleotide sequence of SEQ ID NO: 67, a sense strand having the nucleotide sequence of SEQ ID NO: 68, and an antisense strand having the nucleotide sequence of SEQ ID NO: 69; and
b) treating said subject with said chemotherapeutic agent and said inhibitor.
2. The method of claim 1 , wherein said cytoplasmic tyrosine kinase is Bruton's Tyrosine Kinase.
3. The method of claim 1 , wherein said cytoplasmic tyrosine kinase is a variant of Bruton's Tyrosine Kinase comprising an amino-terminal extension.
4. The method of claim 3 , wherein said extension comprises an additional 34 amino acids.
5. The method of claim 1 , wherein said chemotherapeutic agent comprises Doxorubicin.
6. The method of claim 1 , wherein treating with said chemotherapeutic agent and said inhibitor results in reduced proliferation of the breast cancer cells within said subject.
7. A method of treating cancer, comprising:
a) providing:
i) subject with breast cancer,
ii) a chemotherapeutic agent, and
iii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase, wherein said inhibitor comprises a mixture of interfering double stranded RNAs comprising a sense strand having the nucleotide sequence of SEQ ID NOs: 66 and 68 and an antisense strand having the nucleotide sequence of SEQ ID NOs: 67 and 69; and
b) treating said subject with said chemotherapeutic agent and said inhibitor.
8. The method of claim 1 , A method of treating cancer, comprising:
a) providing:
i) a subject with breast cancer cells, at least some of said breast cancer cells exhibiting resistance to a chemotherapeutic agent, and
ii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase, wherein said inhibitor comprises interfering double stranded RNA selected from the group consisting of: sense strand having the nucleotide sequence of SEQ ID NO: 66, an antisense strand having the nucleotide sequence of SEQ ID NO: 67, a sense strand having the nucleotide sequence of SEQ ID NO: 68, and an antisense strand having the nucleotide sequence of SEQ ID NO: 69, and
b) treating said subject with said inhibitor.
9. The method of claim 8 , wherein said cytoplasmic tyrosine kinase is Bruton's Tyrosine Kinase.
10. The method of claim 8 , wherein said cytoplasmic tyrosine kinase is a variant of Bruton's Tyrosine Kinase comprising an amino-terminal extension.
11. The method of claim 10 , wherein said extension comprises an additional 34 amino acids.
12. The method of claim 8 , wherein treating with said inhibitor results in reduced proliferation of at least some of said breast cancer cells within said subject.
13. The method of claim 8 , wherein said inhibitor results in reduced proliferation of at least some breast cancer cells within said subject identified as resistant to said chemotherapeutic agent.
14. A method of treating cancer, comprising:
a) providing:
i) a subject with breast cancer cells, at least some of said breast cancer cells exhibiting resistance to a chemotherapeutic agent, and
ii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase, wherein said inhibitor comprises a mixture of interfering double stranded RNAs comprising a sense strand having the nucleotide sequence of SEQ ID NOs: 66 and 68 and an antisense strand having the nucleotide sequence of SEQ ID NOs: 67 and 69, and
b) treating said subject with said inhibitor.
15. A method of treating cancer, comprising:
a) providing:
i) a subject with breast cancer,
ii) a chemotherapeutic agent, and
iii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase wherein said inhibitor comprises interfering double stranded RNA selected from the group consisting of: sense strand having the nucleotide sequence of SEQ lD NO: 66, an antisense strand having the nucleotide sequence of SEQ ID NO: 67, a sense strand having the nucleotide sequence of SEQ ID NO: 68, and an antisense strand having the nucleotide sequence of SEQ ID NO: 69,
b) treating said subject with said inhibitor; and
c) after step b), treating said subject with said chemotherapeutic.
16. The method of claim 15 , wherein said cytoplasmic tyrosine kinase is Bruton's Tyrosine Kinase.
17. The method of claim 15 , wherein said cytoplasmic tyrosine kinase is a variant of Bruton's Tyrosine Kinase comprising an amino-terminal extension.
18. The method of claim 17 , wherein said extension comprises an additional 34 amino acids.
19. The method of claim 15 , wherein said chemotherapeutic agent comprises Doxorubicin.
20. The method of claim 15 , wherein treating with said chemotherapeutic agent results in reduced proliferation of the breast cancer cells within said subject.
21. The method of claim 15 , wherein said inhibitor results in reduced proliferation of the breast cancer cells within said subject.
22. A method of treating cancer, comprising:
a) providing:
i) a subject with breast cancer,
ii) a chemotherapeutic agent, and
iii) an inhibitor of a gene encoding a cytoplasmic tyrosine kinase, wherein said inhibitor comprises a mixture of interfering double stranded RNAs comprising a sense strand having the nucleotide sequence of SEQ ID NOs: 66 and 68 and an antisense strand having the nucleotide sequence of SEQ ID NOs: 67 and 69,
b) treating said subject with said inhibitor; and
c) after step b), treating said subject with said chemotherapeutic.